Biomarin Pharmaceutical (BMRN) EBT (2009 - 2026)

Biomarin Pharmaceutical has disclosed EBT across 18 years of filings, most recently posting $141.2 million for Q1 2026.

• Quarterly EBT fell 40.69% year-over-year to $141.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $385.6 million (down 42.82% YoY) and the FY2025 annual result came in at $482.5 million, down 10.94% from the prior year.
• EBT improved to $141.2 million in Q1 2026, from -$27.2 million in the prior quarter.
• Over five years, EBT peaked at $297.9 million in Q2 2025 and troughed at -$27.2 million in Q4 2025.
• A 5-year average of $88.4 million and a median of $70.8 million in 2023 frame the typical range for EBT.
• Annual changes were most pronounced in 2023 — EBT surged 2288.5% — and 2025, when it sank 119.58%.
• Tracing BMRN's EBT over 5 years: stood at -$17.6 million in 2022, then surged by 210.08% to $19.3 million in 2023, then surged by 777.73% to $169.6 million in 2024, then plunged by 116.01% to -$27.2 million in 2025, then soared by 620.03% to $141.2 million in 2026.
• Business Quant data shows BMRN's EBT at $141.2 million in Q1 2026, -$27.2 million in Q4 2025, and -$26.3 million in Q3 2025.